In situ immunization with vidutolimod (Vidu), a virus-like particle containing a CpG-A TLR9 agonist, has demonstrated antitumor activity in preclinical and early-phase clinical studies; however its effect on tumor-specific CD8+ T cells remain poorly defined. The gene discussed is CD8A; the disease is neoplasm.